AbbVie (NYSE: ABBV) is a global biopharmaceutical company long synonymous with its blockbuster drug, Humira. While the drug's ...

AbbVie combines high yield, strong growth from Rinvoq and Skyrizi, and a solid pipeline to support dividends and returns. Find out why ABBV stock is a buy.

AbbVie remains very active in immunology, oncology, and neuroscience. In March, AbbVie made a splash in the obesity field with a partnership with Gubra.

The report provides insights into AbbVie's tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives.

AbbVie raises profit forecast despite potential tariffs on demand for new immunology drugs Drugmaker plans to build four new U.S. sites CEO outlines strategies to mitigate tariff impacts April 25 ...

AbbVie gains control of an in vivo CAR-T therapy that could overcome limitations with currently approved autologous ...

Half of the year is over! So, which pharmaceutical giant outpaces the others? Sharp investors wonder whose market ...

Under the agreement, Neomorph will receive an undisclosed upfront payment from AbbVie and be eligible for up to $1.64 billion in aggregate option fees and milestones.

“Focusing on AbbVie’s immunology segment, Humira’s global revenue of $2.814 billion declined 30% year-over-year given formidable biosimilar competition,” Brown wrote. “AbbVie is doing an excellent job ...

With a diversified portfolio in immunology, oncology, aesthetics, neuroscience, and eye care, AbbVie Inc has shown a resilient financial performance.

AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience strategy and boosting competition for Cobenfy.